Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen’s Lab at Emory University School of Medicine. The collaboration will explore the potential therapeutic benefits of combination therapy…
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary…
European Wellness and Heidelberg University Revolutionize Down Syndrome Research, Moving into Neurodevelopmental and Neurodegenerative Studies
A ground-breaking research collaboration between European Wellness Biomedical Group (EWBG), through its subsidiaries European Wellness Academy (EWA) and Baden R&D Laboratories (Baden), and Heidelberg’s Institute of Anatomy and Cell Biology has yielded new insights into the distinct neuroanatomy and neuropsychology…
